Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 750,525
  • Shares Outstanding, K 170,187
  • Annual Sales, $ 76,200 K
  • Annual Income, $ -17,370 K
  • EBIT $ -22 M
  • EBITDA $ -23 M
  • 60-Month Beta 2.44
  • Price/Sales 10.09
  • Price/Cash Flow N/A
  • Price/Book 7.74

Options Overview Details

View History
  • Implied Volatility 115.81% (+18.72%)
  • Historical Volatility 153.24%
  • IV Percentile 20%
  • IV Rank 7.36%
  • IV High 513.45% on 04/22/25
  • IV Low 84.22% on 03/16/26
  • Expected Move (DTE 17) 0.68 (14.72%)
  • Put/Call Vol Ratio 0.18
  • Today's Volume 157
  • Volume Avg (30-Day) 11,346
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 72,539
  • Open Int (30-Day) 93,039
  • Expected Range 3.94 to 5.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.14
  • Number of Estimates 5
  • High Estimate -0.10
  • Low Estimate -0.17
  • Prior Year 0.27
  • Growth Rate Est. (year over year) -151.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.08 +12.99%
on 03/25/26
8.21 -43.85%
on 03/16/26
-0.76 (-14.15%)
since 02/27/26
3-Month
3.98 +15.80%
on 01/05/26
8.21 -43.85%
on 03/16/26
+0.22 (+5.01%)
since 12/26/25
52-Week
0.40 +1,052.50%
on 04/07/25
8.21 -43.85%
on 03/16/26
+3.98 (+633.84%)
since 03/28/25

Most Recent Stories

More News
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing...

CTMX : 4.59 (+4.08%)
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has...

CTMX : 4.59 (+4.08%)
CytomX Therapeutics: Q4 Earnings Snapshot

CytomX Therapeutics: Q4 Earnings Snapshot

CTMX : 4.59 (+4.08%)
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted...

CTMX : 4.59 (+4.08%)
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

- Confirmed response rates in expansion cohorts of  32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg...

CTMX : 4.59 (+4.08%)
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will...

CTMX : 4.59 (+4.08%)
CytomX Therapeutics to Present at Upcoming February Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management...

CTMX : 4.59 (+4.08%)
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CTMX : 4.59 (+4.08%)
CRDF : 1.6050 (+3.55%)
CytomX Therapeutics Announces Business Update and Company Milestones for 2026

- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal...

CTMX : 4.59 (+4.08%)
CytomX Therapeutics to Present at Upcoming December Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management...

CTMX : 4.59 (+4.08%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 4.79
2nd Resistance Point 4.65
1st Resistance Point 4.53
Last Price 4.59
1st Support Level 4.27
2nd Support Level 4.13
3rd Support Level 4.01

See More

52-Week High 8.21
Fibonacci 61.8% 5.23
Last Price 4.59
Fibonacci 50% 4.30
Fibonacci 38.2% 3.38
52-Week Low 0.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.